BCL2 and B-cell chronic lymphocytic leukemia: Finally, we explored the potential of combining AZ1 with venetoclax, a BCL-2 inhibitor, or ibrutinib, a BTK inhibitor, which are both commonly used in the treatment of CLL patients.